Department of Molecular and Cellular Biology, Arizona Cancer Center and BIO5 Institute, University of Arizona, Tucson, AZ, USA.
Cell Adh Migr. 2013 Mar-Apr;7(2):187-98. doi: 10.4161/cam.23131. Epub 2013 Jan 9.
MUC1 is a transmembrane mucin that is often overexpressed in metastatic cancers and often used as a diagnostic marker for metastatic progression. The extracellular domain of MUC1 can serve as a ligand for stromal and endothelial cell adhesion receptors, and the cytoplasmic domain engages in several interactions that can result in increased migration and invasion, as well as survival. In this review, we address the role of MUC1 in metastatic progression by assessing clinical studies reporting MUC1 levels at various disease stages, reviewing mouse models utilized to study the role of MUC1 in metastatic progression, discuss mechanisms of MUC1 upregulation, and detail MUC1 protein interactions and signaling events. We review interactions between MUC1 and the extracellular environment, with proteins colocalized in the plasma membrane and/or cytoplasmic proteins, and summarize the role of MUC1 in the nucleus as a transcriptional cofactor. Finally, we review recent publications describing current therapies targeting MUC1 in patients with advanced disease and the stage of these therapies in preclinical development or clinical trials.
MUC1 是一种跨膜粘蛋白,在转移性癌症中常过表达,常被用作转移性进展的诊断标志物。MUC1 的细胞外结构域可作为基质和内皮细胞黏附受体的配体,而细胞质结构域则参与几种相互作用,导致迁移和侵袭增加以及存活。在这篇综述中,我们通过评估报告各种疾病阶段 MUC1 水平的临床研究,利用研究 MUC1 在转移性进展中作用的小鼠模型,讨论 MUC1 上调的机制,并详细介绍 MUC1 蛋白相互作用和信号事件,来探讨 MUC1 在转移性进展中的作用。我们综述了 MUC1 与细胞外环境之间的相互作用,包括在质膜共定位的蛋白质和/或细胞质蛋白质,并总结了 MUC1 在核内作为转录共因子的作用。最后,我们综述了描述针对晚期疾病患者中 MUC1 的当前治疗方法的最新出版物,以及这些治疗方法在临床前开发或临床试验中的阶段。